DexCom (DXCM) Stock Price, News & Analysis

Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $69.08 to $70.62
• 50-Day Range: $64.00 to $116.06
• 52-Week Range: $62.34 to $142.00
• Volume: 3.42 million shs
• Average Volume: 3.79 million shs
• Market Capitalization: $27.62 billion
• P/E Ratio: 44.81
• Dividend Yield: N/A
• Price Target: $112.25
• Consensus Rating: Moderate Buy

DexCom Stock Analysis - MarketRank™

DexCom scored higher than 100% of companies evaluated by MarketBeat, and ranked 6th out of 1,017 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 11 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

DexCom has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 18.93%

Earnings Growth

Earnings for DexCom are expected to grow by 18.93% in the coming year, from $1.69 to $2.01 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DexCom is 44.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of DexCom is 44.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.22.

Price to Earnings Growth Ratio

DexCom has a PEG Ratio of 2.12. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

DexCom has a P/B Ratio of 12.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.84% of the outstanding shares of DexCom have been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently decreased by 3.04%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DexCom does not currently pay a dividend.

Dividend Growth

DexCom does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.76

Percentage of Shares Shorted

1.84% of the outstanding shares of DexCom have been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently decreased by 3.04%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.13

News Sentiment

DexCom has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 47 news articles for DexCom this week, compared to 17 articles on an average week.

Search Interest

Only 34 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $201,708.00 in company stock.

Percentage Held by Insiders

Only 0.30% of the stock of DexCom is held by insiders.

Percentage Held by Institutions

97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DXCM Stock Analysis - Frequently Asked Questions

How have DXCM shares performed this year?

DexCom's stock was trading at $124.09 at the beginning of 2024. Since then, DXCM stock has decreased by 44.0% and is now trading at $69.46.
View the best growth stocks for 2024 here.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its earnings results on Thursday, July, 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The business's quarterly revenue was up 15.3% compared to the same quarter last year.
Read the conference call transcript.

When did DexCom's stock split?

DexCom shares split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Does DexCom have any subsidiaries?

DexCom subsidiaries include TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and others.

Who are DexCom's major shareholders?

Top institutional investors of DexCom include Baillie Gifford & Co. (3.85%), Legal & General Group Plc (0.75%), Massachusetts Financial Services Co. MA (0.61%) and Vaughan Nelson Investment Management L.P. (0.41%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson, Barbara Kahn, Richard Alexander Collins, Mark G Foletta and Nicholas Augustinos.
View institutional ownership trends.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 7/25/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 10/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:DXCM
• CUSIP: 25213110
• CIK: 1093557
• Web: www.dexcom.com
• Phone: (858) 200-0200
• Fax: 858-200-0201
• Employees: 9,600
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $112.25
• High Stock Price Target: $161.00
• Low Stock Price Target: $75.00
• Potential Upside/Downside: +61.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.72
• Research Coverage: 18 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.55
• Trailing P/E Ratio: 44.81
• Forward P/E Ratio: 41.10
• P/E Growth: 2.12
• Net Income: $541.50 million
• Net Margins: 16.95%
• Pretax Margin: 20.51%
• Return on Equity: 31.41%
• Return on Assets: 10.84%

Debt

• Debt-to-Equity Ratio: 1.00
• Current Ratio: 2.82
• Quick Ratio: 2.48

Sales & Book Value

• Annual Sales: $3.93 billion
• Price / Sales: 7.02
• Cash Flow: $2.10 per share
• Price / Cash Flow: 33.09
• Book Value: $5.35 per share
• Price / Book: 12.98

Miscellaneous

• Outstanding Shares: 397,684,000
• Free Float: 396,491,000
• Market Cap: $27.62 billion
• Optionable: Optionable
• Beta: 1.18